Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 6,602	$ 16,660
Restricted cash	4	4
Prepaid expenses and other current assets	177	461
Total current assets	6,783	17,125
Property, equipment and leasehold improvements, net	73	100
Restricted cash - non current	110	110
Operating lease right-of-use assets	1,211
Prepaid clinical trial expenses	1,122	996
Other assets	26	46
Total assets	9,325	18,377
Current liabilities:
Accounts payable	942	815
Loan payable, current portion		100
Operating lease liabilities	294
Accrued expenses	1,427	1,290
Total current liabilities	2,663	2,205
Other liabilities	59	61
Operating lease liabilities - non current	1,020
Total liabilities	3,742	2,266
Commitments and contingencies (Note 15)
Stockholders’ equity:
Common stock, $0.00001 par value, authorized 16,666,667 shares; 550,736 shares issued and outstanding, including 6,886 shares of unvested restricted stock, at December 31, 2019; 310,330 shares issued and outstanding at December 31, 2018	2	1
Additional paid-in capital	224,741	223,440
Accumulated deficit	(219,160)	(207,330)
Total stockholders’ equity	5,583	16,111
Total liabilities and stockholders’ equity	$ 9,325	$ 18,377